Streetbeat News

DNA

Ginkgo Bioworks Holdings, Inc.

https://www.ginkgobioworks.com

Industry

Biotechnology

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Open

8.30

Mkt cap

472M

Volume

498K

High

8.56

P/E Ratio

-0.47

52-wk high

75.20

Low

8.13

Div yield

N/A

52-wk low

5.26

Diodes Incorporated shares fell by approximately 10% after reporting quarterly financial results that missed market expectations. Other stocks experienced significant movements, with notable gainers including Novavax, Inc. and iTeos Therapeutics, Inc., and losers like MacroGenics, Inc. and Greenwave Technology Solutions, Inc.

Portfolio Pulse from Avi Kapoor

May 10, 2024 | 4:44 pm

William Blair analyst Matt Larew downgrades Ginkgo Bioworks Holdings (NYSE:DNA) from Market Perform to Underperform.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 1:49 pm

Ginko Bioworks Holdings' shares dropped following the announcement of Q1 sales results that fell short of expectations.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 10:59 am

Akamai Technologies issued a weak outlook, causing its shares to fall sharply in pre-market trading. Other companies like MacroGenics, Progyny, MicroVision, Applied Optoelectronics, JFrog, Navitas Semiconductor, Ginkgo Bioworks, indie Semiconductor, Yelp, and Runway Growth Finance also reported losses due to various negative financial results or guidance.

Portfolio Pulse from Avi Kapoor

May 10, 2024 | 9:45 am

Ginko Bioworks Holdings reported worse-than-expected Q1 sales results, leading to a decrease in their share price.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:50 pm

Ginkgo Bioworks Holdings, Inc. (NASDAQ:DNA) reported Q1 sales of $38 million, missing analyst estimates by 17.47% and marking a 52.91% decrease year-over-year, primarily due to a ramp down in K-12 testing in its Biosecurity segment. Cell Engineering revenue decreased by 18%, while Biosecurity revenue was $10 million with an 8% gross profit margin. CEO Jason Kelly expressed disappointment and announced a plan for adjusted EBITDA break-even by end of 2026, including significant cost reductions.

Portfolio Pulse from Erica Kollmann

May 09, 2024 | 8:50 pm

Ginkgo Bioworks Holdings (NYSE:DNA) reported Q1 2024 earnings with a GAAP EPS of $(0.08), surpassing the $(0.09) estimate. However, their sales of $38M fell short of the $46.044M estimate, marking a 52.91% decrease from the previous year's $80.702M.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:43 pm

Ginkgo Bioworks Holdings (NYSE:DNA) reported Q1 sales of $38M, missing the consensus estimate of $46.044M by 17.47%, and marking a 52.91% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:03 pm

GreenLab has announced a partnership with Ginkgo Bioworks to increase the production of Brazzein, a new sweetener. This collaboration aims to leverage Ginkgo Bioworks' biotechnology expertise to scale up the manufacturing process of Brazzein, which is known for its high sweetness level and low-calorie content, making it a promising alternative to traditional sugar and artificial sweeteners.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:06 am

Clever Leaves Holdings Inc. announced its decision to voluntarily delist from Nasdaq, causing a 60% drop in its shares. Other stocks moved significantly in Monday's session, with Deciphera Pharmaceuticals surging 73% after an acquisition announcement, and various companies like Collective Audience and ImmunityBio also seeing substantial gains. Losers included Annovis Bio, down 57% after disappointing trial results, and Addex Therapeutics, falling 48.8% due to a failed epilepsy study.

Portfolio Pulse from Avi Kapoor

April 29, 2024 | 5:04 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.